Skip to main content
. 2014 Oct 10;2014(10):CD000169. doi: 10.1002/14651858.CD000169.pub3

Greenwood 1989 GMB.

Methods Trial design: Trial randomized by compound
Data collected: 1984 to 1987
Length of follow‐up: from first prenatal visit until one week after delivery
Frequency of follow‐up: unclear but administration was on weekly basis
Participants Parity: all women
Number: 1049
Inclusion criteria: all women in trial villages who became pregnant; some sub‐studies only followed up primigravidae
Excluded: none stated
Interventions
  1. Pyrimethamine 25 mg and dapsone 100 mg: fortnightly

  2. Placebo


Given by village people employed by the project
Other: no information
Administration supervised: yes
Outcomes
  1. Antenatal parasitaemia

  2. Birthweight

  3. Packed cell volume

  4. Maternal death

  5. Perinatal death

  6. Infant death

Notes Location: The Gambia
Urban/rural: urban
Malaria transmission: seasonal
Drug resistance: none reported
Funding: Unclear
For the analysis we assumed that it is individually RCT
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence generation (selection bias) Unclear risk "Once a woman had reported to a traditional birth attendant that she was pregnant, she was allocated to receive one tablet of Maloprim fortnightly or placebo and issued with a record card by an MRC field worker. Randomization was by compound."
No details provided of a specific procedure used to generate allocation sequence.
Allocation concealment (selection bias) Unclear risk "Treatment was indicated on the record card by a pictorial representation of a coloured tablet (white for Maloprim,  pink for placebo)".
Insufficient details provided.
Blinding (performance bias and detection bias) 
 All outcomes Low risk Placebo tablets used.
Blinding of outcome assessment (detection bias) 
 All outcomes Unclear risk No details provided.
Incomplete outcome data (attrition bias) 
 All outcomes Unclear risk "1208 pregnancies which progressed beyond the 28th week were recorded during the 3 years of the survey. During 1049 (87%) of these pregnancies women reported to the TBA resident and received one or more doses of Maloprim or placebo."
Unclear risk. Assumption is that attrition rate was 13.2% (159/1208, where 159 = 1208‐1049).
Selective reporting (reporting bias) Low risk No apparent risk.
Other bias Low risk None identified.